NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Patented Enzymatic Ibuprofen Synthesis and Sustainable Pharmaceutical Innovation
TL;DR
Quantumzyme's patented enzyme technology provides a competitive edge in sustainable ibuprofen manufacturing through reduced waste and enhanced efficiency.
Quantumzyme's enzymatic process uses AI-driven optimization and molecular modeling to synthesize ibuprofen while eliminating harsh chemicals and reducing waste.
This sustainable manufacturing approach creates a cleaner pharmaceutical industry with reduced environmental impact for future generations.
Quantumzyme engineers enzymes using quantum mechanics and AI to produce ibuprofen through biological processes instead of traditional chemistry.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme announced the WIPO publication of its international patent application for 'Modified Polypeptides for Enzymatic Synthesis of Ibuprofen' (WO 2025/093935 A1) and highlighted its previously published U.S. patent application covering related enzymatic processes.
This validates the strength of their enzyme engineering technology, strengthens their international intellectual property portfolio, and enhances their position for global partnerships focused on greener pharmaceutical manufacturing.
The process uses proprietary biocatalytic methods through an enzyme-mediated process designed to reduce chemical waste, eliminate harsh reagents, and enhance overall manufacturing efficiency, built on their QZyme Workbench™ platform.
The patented synthesis builds on Quantumzyme's proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts.
The WIPO international patent was published in May 2025, and the U.S. Patent Application (US 2025/0146029 A1) was published previously, though the company is announcing them now to highlight ongoing progress.
The process reduces chemical waste, eliminates harsh reagents, and enhances overall manufacturing efficiency compared to traditional chemical synthesis methods.
The company intends to continue laboratory optimization and scale-up validation, pursue discussions with global pharmaceutical companies and CMOs for licensing or joint-development, and file additional patent applications for related enzymatic transformations.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated that the patent publications validate their enzyme engineering technology and allow them to advance into optimization, pilot-testing, and engaging with potential partners for sustainable API production.
For more information and updates, visit their website at www.quantumzymecorp.com and the Company's profile at www.otcmarkets.com/stock/QTZM.
The QZyme Workbench™ platform underpins multiple enzyme systems the company is developing for sustainable, high-efficiency production of active pharmaceutical ingredients (APIs) and specialty chemicals.
Curated from NewMediaWire
